June 15, 2020 — A novel treatment for advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to new research. PAYS Paysign $8.06 / -2.33 (-22.43%). Although the FDA will consider the recommendation of the panel, the final decision regarding the approval of the product is made solely by the FDA, and the recommendations by the panel are non-binding. See what's happening in the market right now with MarketBeat's real-time news feed. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated,... Data are provided 'as is' for informational purposes only and are not intended for trading purposes.
If approved by the PDUFA date, Mesoblast plans to launch RYONCIL in the United States in 2020.The Committee discusses Mesoblast's Biologics License Application (BLA) 125706 for Remestemcel-L (ex-vivo culture-expanded adult human mesenchymal stromal cells suspension for intravenous infusion) in a virtual meeting being held on August 13 at 8 am.